NBTXNanobiotix S.A.

NBTX Stock Price, Valuation & Chart | Nanobiotix S.A.

Compare

$41.670+2.38 (+6.06%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NBTX intrinsic value NBTX calculated fair value vs price

Overview Financials Dividends Ratios

NBTX Historical price chart

NBTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.11B

PE Ratio-70.42

EPS-0.59

Trading Volume185.25K

Today's High/Low43.38/40.63

Dividend Yield0.00

52 Week High/Low57.14/8.03

Shares Outstanding50.60M

NBTX Financial Statement

NBTX Analyst ratings

NBTX Analysis & performance metrics

NBTX Company profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous…

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and…

NBTX Management team

Name

Position

Earl J. Bergey Ph.d.

Co-Founder

Leonard A. Farber M.D.

Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board

Bart Van RhijnCFO

Chief Financial & Business Officer and Member of Executive Board

Brandon Owens

Vice President of Strategic Marketing & Corporate Communication

Craig West CFA

Senior Vice President of Investor Relations

Margaret Galluzzi

Vice President & Global Head of Clinical Operations

Laurent Levy Ph.D.CEO

Co-Founder, President of the Executive Board & Chief Executive Officer

Louis Kayitalire M.D.

Chief Medical Officer & Member of Executive Board

Name

Position

Earl J. Bergey Ph.d.

Co-Founder

Leonard A. Farber M.D.

Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board

Bart Van RhijnCFO

Chief Financial & Business Officer and Member of Executive Board

Brandon Owens

Vice President of Strategic Marketing & Corporate Communication

Craig West CFA

Senior Vice President of Investor Relations

Margaret Galluzzi

Vice President & Global Head of Clinical Operations

Laurent Levy Ph.D.CEO

Co-Founder, President of the Executive Board & Chief Executive Officer

Louis Kayitalire M.D.

Chief Medical Officer & Member of Executive Board

Management Team

Earl J. Bergey Ph.d.

Co-Founder

Leonard A. Farber M.D.

Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board

Bart Van RhijnCFO

Chief Financial & Business Officer and Member of Executive Board

Brandon Owens

Vice President of Strategic Marketing & Corporate Communication

Craig West CFA

Senior Vice President of Investor Relations

Margaret Galluzzi

Vice President & Global Head of Clinical Operations

Laurent Levy Ph.D.CEO

Co-Founder, President of the Executive Board & Chief Executive Officer

Louis Kayitalire M.D.

Chief Medical Officer & Member of Executive Board

Management

Earl J. Bergey Ph.d.

Co-Founder

Leonard A. Farber M.D.

Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board

Bart Van RhijnCFO

Chief Financial & Business Officer and Member of Executive Board

Brandon Owens

Vice President of Strategic Marketing & Corporate Communication

Craig West CFA

Senior Vice President of Investor Relations

Margaret Galluzzi

Vice President & Global Head of Clinical Operations

Laurent Levy Ph.D.CEO

Co-Founder, President of the Executive Board & Chief Executive Officer

Louis Kayitalire M.D.

Chief Medical Officer & Member of Executive Board

Total 8 executives

NBTX Frequently asked questions

What is Nanobiotix S.A. (NBTX) Stock Price?

Current stock price of Nanobiotix S.A. (NBTX) stock is $41.670. The stock price is +6.06% higher in the session. The intraday range can be seen from this page. Volume of Nanobiotix S.A. (NBTX) stock is 185.25K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Nanobiotix S.A. (NBTX) stock price going up or down today?

The stock price of Nanobiotix S.A. (NBTX) can change with earnings, company news, and overall market sentiment. Nanobiotix S.A. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Nanobiotix S.A. stock expensive at its current price?

Whether Nanobiotix S.A. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NBTX on this page is -70.42. EPS on this page is -0.59. Compare those figures with peers and growth expectations before deciding if the current Nanobiotix S.A. price is justified.

How has the stock price of Nanobiotix S.A. (NBTX) performed historically?

Historical performance for Nanobiotix S.A. (NBTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NBTX reacted to past earnings and market events.

Should I buy Nanobiotix S.A. (NBTX) stock, at this price?

Buying Nanobiotix S.A. (NBTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.